Hematology & Oncology
Mantle Cell Lymphoma
~7 min read8 sections
Contents (8)
Mantle cell lymphoma accounts for roughly 5-7% of non-Hodgkin lymphomas and has historically occupied an unenviable middle ground: it behaves aggressively like a high-grade lymphoma while remaining incurable with conventional therapy like an indolent one — the worst features of both categories in one disease.
It is defined by the t(11;14) translocation and consequent cyclin D1 overexpression, which drives cells through the G1/S checkpoint. Patients are typically men in their late sixties — the male predominance is striking, roughly 3:1 — and present with widespread disease, with around 70% at stage IV.
Two things have changed the picture substantially. First, BTK inhibitors transformed relapsed disease and are now moving into first-line therapy. Second, it is now clear that mantle cell lymphoma is not one disease: a leukaemic non-nodal, SOX11-negative variant behaves indolently and may warrant observation, while the blastoid and pleomorphic variants and TP53-mutated disease are genuinely aggressive and respond poorly to chemoimmunotherapy. Treating all three the same way is the commonest strategic error.
- The t(11;14)(q13;q32) translocation juxtaposes CCND1 on chromosome 11 with the immunoglobulin heavy chain enhancer on chromosome 14, producing constitutive cyclin D1 overexpression
- Cyclin D1 partners with CDK4 and CDK6 to phosphorylate retinoblastoma protein, releasing E2F and driving cells from G1 into S phase. The lesion is therefore one of unchecked cell cycle entry, in contrast to the anti-apoptotic lesion of follicular lymphoma
- The tumour arises from a naive pre-germinal-centre B cell of the mantle zone, which is why it retains CD5 expression and generally lacks germinal-centre markers
- SOX11, a transcription factor, is expressed in classic nodal disease and absent in the leukaemic non-nodal variant — the single most useful marker separating aggressive from indolent biology. SOX11 is also valuable in the uncommon cyclin D1-negative cases
- t(11;14) alone is insufficient: additional lesions determine behaviour. TP53 mutation or deletion is the dominant adverse event, conferring chemoresistance; CDKN2A deletion, ATM mutation, NOTCH1/2 mutations and high Ki-67 mark aggressive disease
- Blastoid and pleomorphic morphology reflects accumulated genomic damage and behaves like a high-grade lymphoma, including a propensity for CNS involvement
- Age — median at diagnosis around 65-70; uncommon before 50
- Male sex — a pronounced male predominance of roughly 3:1, among the strongest of any lymphoma
- More frequent in white populations than in Asian or African populations
- Family history of lymphoid malignancy confers a modest increase
- In situ mantle cell neoplasia — cyclin D1-positive cells confined to mantle zones, found incidentally — is a precursor state that rarely progresses and should not be treated as lymphoma
- No infectious agent, occupational exposure or lifestyle factor is established as causative
- Widespread lymphadenopathy at presentation, with stage III-IV disease in roughly 70%
- Splenomegaly, often marked, and hepatomegaly
- Bone marrow involvement in the majority, and peripheral blood involvement frequently, sometimes with a markedly elevated lymphocyte count that can be mistaken for CLL
- Gastrointestinal involvement is characteristic — lymphomatous polyposis, in which innumerable small mucosal polyps stud the colon and small bowel. Occult gastrointestinal involvement is present in most patients if biopsied, even when asymptomatic
- Waldeyer ring involvement is common
- B symptoms and fatigue in a substantial minority
- CNS involvement occurs, particularly with blastoid morphology, high Ki-67, or relapsed disease, and carries a poor prognosis
- The leukaemic non-nodal variant presents differently: peripheral blood and marrow involvement with splenomegaly but little or no lymphadenopathy, often asymptomatic and discovered on a routine blood count
Tissue and immunophenotype
- Excisional lymph node biopsy where possible; marrow or blood flow cytometry may suffice in the leukaemic variant
- Histology: monomorphic small-to-medium lymphoid cells with irregular nuclear contours, in a diffuse, nodular or mantle-zone pattern. Blastoid and pleomorphic variants show larger cells and a high mitotic rate
- Immunophenotype: CD19, CD20, CD5 and FMC7 positive, with cyclin D1 positive — the diagnostic finding — and SOX11 positive in classic disease
- CD23 is negative or weak, and CD200 negative. This is the crucial separation from CLL/SLL, which is CD5-positive and CD23-positive. Both are CD5-positive B-cell neoplasms, and CD23 plus cyclin D1 distinguishes them
- CD10 and BCL6 negative, separating it from follicular lymphoma and Burkitt
- FISH for t(11;14) confirms the diagnosis, and is essential in cyclin D1-negative cases where SOX11 carries the diagnosis
Staging and risk assessment
- PET-CT, bone marrow aspirate and biopsy, and endoscopy with biopsy where gastrointestinal symptoms exist
- Ki-67 proliferation index — the most important pathological prognostic variable; above roughly 30% marks adverse disease
- TP53 mutation testing should be performed in all patients, because TP53-mutated disease responds poorly to intensive chemoimmunotherapy and this changes the treatment plan rather than merely the prognosis
- MIPI (Mantle Cell Lymphoma International Prognostic Index): age, ECOG performance status, LDH and white cell count; the combined biological MIPI incorporates Ki-67
- Lumbar puncture in blastoid disease or where neurological symptoms exist
Decide first which disease you are treating
- Leukaemic non-nodal, SOX11-negative disease without adverse features may be observed, sometimes for years — treating it immediately is a recognized error
- TP53-mutated disease responds poorly to intensive chemoimmunotherapy and should be directed toward novel agents, cellular therapy or clinical trials rather than aggressive cytotoxic induction
Younger, fit patients
- Induction incorporating high-dose cytarabine — for example alternating R-CHOP with R-DHAP, or the Nordic regimen — followed by autologous stem cell transplantation and rituximab maintenance has been the long-standing standard
- The TRIANGLE trial showed that adding ibrutinib to induction and maintenance improved outcomes, and that the ibrutinib-containing arm without transplantation performed comparably to the arm with it — calling the routine role of autologous transplantation into question. Practice is actively shifting
Older or less fit patients
- Bendamustine with rituximab is widely used and well tolerated
- VR-CAP (substituting bortezomib for vincristine) or R-CHOP are alternatives
- Rituximab maintenance prolongs survival after R-CHOP induction in older patients
Relapsed and refractory disease
- BTK inhibitors are the mainstay: acalabrutinib and zanubrutinib are preferred over ibrutinib for tolerability, particularly regarding atrial fibrillation and bleeding
- Venetoclax, lenalidomide and bortezomib have activity
- Brexucabtagene autoleucel, a CD19 CAR T-cell product, produces high and durable response rates in BTK-inhibitor-exposed disease and is a major advance
- Allogeneic transplantation remains an option for selected young patients
- CNS prophylaxis or treatment with high-dose methotrexate in blastoid or CNS-involved disease
- Progressive, ultimately treatment-refractory disease — most patients relapse, and conventional therapy is not curative
- Gastrointestinal bleeding, obstruction or intussusception from lymphomatous polyposis
- Cytopenias from marrow infiltration and hypersplenism, with infection and bleeding risk
- CNS involvement, particularly blastoid disease, which is difficult to treat and carries poor survival
- Blastoid transformation of previously indolent disease
- BTK inhibitor toxicity: atrial fibrillation, hypertension and bleeding — most pronounced with ibrutinib and reduced with acalabrutinib and zanubrutinib
- CAR T-cell toxicity: cytokine release syndrome, ICANS, prolonged cytopenias and hypogammaglobulinaemia
- Cytarabine toxicity: cerebellar dysfunction, conjunctivitis and profound myelosuppression
- Secondary myelodysplasia and acute myeloid leukaemia after alkylators and autologous transplantation
- Hepatitis B reactivation after rituximab in unscreened patients
- Tumour lysis syndrome, particularly with venetoclax and in high-burden blastoid disease
- t(11;14) drives cyclin D1 overexpression, pushing cells through the G1/S checkpoint — a cell-cycle lesion, in contrast to the anti-apoptotic BCL2 lesion of follicular lymphoma
- Both mantle cell and CLL/SLL are CD5-positive B-cell neoplasms. Mantle cell is CD23-negative and cyclin D1-positive; CLL is CD23-positive and cyclin D1-negative. This is the single most examined distinction in the disease
- Lymphomatous polyposis — innumerable small bowel and colonic polyps — is the classic gastrointestinal presentation, and occult gut involvement is present in most patients
- SOX11 separates the two biologies: SOX11-positive classic nodal disease is aggressive; SOX11-negative leukaemic non-nodal disease is indolent and may be observed
- Test TP53 in everyone. TP53-mutated disease resists intensive chemoimmunotherapy, and the result should redirect therapy toward novel agents or cellular therapy rather than merely inform prognosis
- Ki-67 above about 30% and blastoid or pleomorphic morphology mark aggressive disease with CNS risk
- MIPI uses age, performance status, LDH and white cell count
- BTK inhibitors transformed relapsed disease; acalabrutinib and zanubrutinib are preferred over ibrutinib because of less atrial fibrillation and bleeding
- The TRIANGLE trial questioned routine autologous transplantation in younger patients when ibrutinib is incorporated into induction and maintenance
- Brexucabtagene autoleucel is highly effective after BTK inhibitor failure
- A markedly raised lymphocyte count in mantle cell can mimic CLL — always check cyclin D1 and CD23 before accepting a CLL diagnosis
- In situ mantle cell neoplasia is an incidental finding, not a lymphoma — do not treat it